Meike Vogler

List of Publications by Year
in descending order

38 papers	1,933 citations	331670 21 h-index	315739 38 g-index
39 all docs	39 docs citations	39 times ranked	2957 citing authors

#	Article	IF	Citations
1	Unleashing the power of NK cells in anticancer immunotherapy. Journal of Molecular Medicine, 2022, 100, 337-349.	3.9	12
2	Pediatric multicellular tumor spheroid models illustrate a therapeutic potential by combining BH3 mimetics with Natural Killer (NK) cell-based immunotherapy. Cell Death Discovery, 2022, 8, 11.	4.7	7
3	It's time to die: BH3 mimetics in solid tumors. Biochimica Et Biophysica Acta - Molecular Cell Research, 2021, 1868, 118987.	4.1	40
4	Next-generation hypomethylating agent SGI-110 primes acute myeloid leukemia cells to IAP antagonist by activating extrinsic and intrinsic apoptosis pathways. Cell Death and Differentiation, 2020, 27, 1878-1895.	11.2	8
5	DLBCL Cells with Acquired Resistance to Venetoclax Are Not Sensitized to BIRD-2 But Can Be Resensitized to Venetoclax through Bcl-XL Inhibition. Biomolecules, 2020, 10, 1081.	4.0	9
6	BDA-366, a putative Bcl-2 BH4 domain antagonist, induces apoptosis independently of Bcl-2 in a variety of cancer cell models. Cell Death and Disease, 2020, 11, 769.	6.3	15
7	MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents. Journal of Hematology and Oncology, 2020, 13, 173.	17.0	91
8	A direct comparison of selective BH3-mimetics reveals BCL-XL, BCL-2 and MCL-1 as promising therapeutic targets in neuroblastoma. British Journal of Cancer, 2020, 122, 1544-1551.	6.4	19
9	Targeting BCL-2 proteins in pediatric cancer: Dual inhibition of BCL-XL and MCL-1 leads to rapid induction of intrinsic apoptosis. Cancer Letters, 2020, 482, 19-32.	7.2	41
10	Specific interactions of BCL-2 family proteins mediate sensitivity to BH3-mimetics in diffuse large B-cell lymphoma. Haematologica, 2020, 105, 2150-2163.	3.5	30
11	Proteasome inhibitors and Smac mimetics cooperate to induce cell death in diffuse large Bâ€cell lymphoma by stabilizing NOXA and triggering mitochondrial apoptosis. International Journal of Cancer, 2020, 147, 1485-1498.	5.1	6
12	Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML. Cell Death and Disease, 2019, 10, 917.	6.3	27
13	Targeting intermediary metabolism enhances the efficacy of BH3 mimetic therapy in hematologic malignancies. Haematologica, 2019, 104, 1016-1025.	3.5	14
14	Identification of Smac mimetics as novel substrates for p-glycoprotein. Cancer Letters, 2019, 440-441, 126-134.	7.2	8
15	Selective BH3-mimetics targeting BCL-2, BCL-X_L or MCL-1 induce severe mitochondrial perturbations. Biological Chemistry, 2019, 400, 181-185.	2.5	8
16	NRAS-Mutated Rhabdomyosarcoma Cells Are Vulnerable to Mitochondrial Apoptosis Induced by Coinhibition of MEK and PI3KÎ±. Cancer Research, 2018, 78, 2000-2013.	0.9	15
17	Co-targeting of BET proteins and HDACs as a novel approach to trigger apoptosis in rhabdomyosarcoma cells. Cancer Letters, 2018, 428, 160-172.	7.2	38
18	BCL-xL-selective BH3 mimetic sensitizes rhabdomyosarcoma cells to chemotherapeutics by activation of the mitochondrial pathway of apoptosis. Cancer Letters, 2018, 412, 131-142.	7.2	24

#	Article	IF	Citations
19	BCL-2 selective inhibitor ABT-199 primes rhabdomyosarcoma cells to histone deacetylase inhibitor-induced apoptosis. Oncogene, 2018, 37, 5325-5339.	5.9	29
20	Responses to the Selective Brutonâ€™s Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines. Cancers, 2018, 10, 127.	3.7	26
21	S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth. Oncotarget, 2018, 9, 20075-20088.	1.8	82
22	Targeting antiâ€apoptotic <scp>BCL</scp>2 family proteins in haematological malignancies â€“ from pathogenesis to treatment. British Journal of Haematology, 2017, 178, 364-379.	2.5	74
23	Targeting BCL2-Proteins for the Treatment of Solid Tumours. Advances in Medicine, 2014, 2014, 1-14.	0.8	80
24	<scp>ABT</scp>â€199 selectively inhibits <scp>BCL</scp>2 but not <scp>BCL</scp>2<scp>L</scp>1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets. British Journal of Haematology, 2013, 163, 139-142.	2.5	93
25	Precision medicines for Bâ€cell leukaemias and lymphomas; progress and potential pitfalls. British Journal of Haematology, 2013, 160, 725-733.	2.5	11
26	Response: BH3 mimetics modulate calcium homeostasis in platelets. Blood, 2012, 119, 1321-1322.	1.4	12
27	The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein. Biochemical and Biophysical Research Communications, 2011, 408, 344-349.	2.1	16
28	BCL2/BCL-XL inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation. Blood, 2011, 117, 7145-7154.	1.4	161
29	Diminished Sensitivity of Chronic Lymphocytic Leukemia Cells to ABT-737 and ABT-263 Due to Albumin Binding in Blood. Clinical Cancer Research, 2010, 16, 4217-4225.	7.0	45
30	Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells. Haematologica, 2010, 95, 1510-1518.	3.5	73
31	Small Molecule XIAP Inhibitors Enhance TRAIL-Induced Apoptosis and Antitumor Activity in Preclinical Models of Pancreatic Carcinoma. Cancer Research, 2009, 69, 2425-2434.	0.9	140
32	Response: Microenvironment-dependent resistance to ABT-737 in chronic lymphocytic leukemia. Blood, 2009, 114, 2561-2562.	1.4	9
33	Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2â€“mediated resistance. Blood, 2009, 113, 1710-1722.	1.4	127
34	Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood, 2009, 113, 4403-4413.	1.4	294
35	Targeting XIAP Bypasses Bcl-2â€“Mediated Resistance to TRAIL and Cooperates with TRAIL to Suppress Pancreatic Cancer Growth In vitro and In vivo. Cancer Research, 2008, 68, 7956-7965.	0.9	143
36	Small Molecule XIAP Inhibitors Cooperate with TRAIL to Trigger Apoptosis in Childhood Acute Leukemia Cells and Overcome Bcl-2-Mediated Resistance. Blood, 2008, 112, 857-857.	1.4	2

#	Article	IF	Citations
37	Inhibition of clonogenic tumor growth: a novel function of Smac contributing to its antitumor activity. Oncogene, 2005, 24, 7190-7202.	5.9	40
38	Sensitization for Î³-Irradiationâ€“Induced Apoptosis by Second Mitochondria-Derived Activator of Caspase. Cancer Research, 2005, 65, 10502-10513.	0.9	64